Synthesis and anticancer evaluation of 4’-thio and 4’-sulfinyl pyrimidine nucleoside analogues

27 October 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Analogues of the canonical nucleosides required for nucleic acid synthesis have a longstanding presence and proven capability within antiviral and anticancer research. Despite their success, newer generations of such analogues are required, to overcome issues surrounding cellular proficiency and growing resistance profiles. The chemical synthesis of a series of nucleoside analogues that incorporate bioisosteric replacement of furanose oxygen with sulfur is presented herein. Developing access to a common 4-thioribose building block enables access to thio-ribo and thio-arabino pyrimidine nucleosides, alongside their 4’-sulfinyl derivatives. In addition, this building block methodology is templated to deliver 4’-thio and 4’-sulfinyl analogues of the established anticancer drug gemcitabine. Cytotoxic capability of these new analogues is evaluated against human pancreatic cancer and human primary glioblastoma cell lines, with observed activities ranging from low μM to >200 μM; explanation for this reduced activity, compared to established nucleoside analogues, is yet unclear. Access to these chemotypes, with thiohemiaminal linkages, will enable a wider exploration of such materials for resistance towards relevant hydrolytic enzymes within nucleotide and nucleic acid biochemistries.


nucleoside analogue


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.